(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 30 October 2003 (30.10.2003)

PCT

(10) International Publication Number WO 03/089001 A1

(51) International Patent Classification⁷: A61K 45/00, 45/06, 38/04, 38/16, 39/395, A61P 15/00, 35/00, A61K 9/00

(21) International Application Number: PCT/GB03/01521

(22) International Filing Date: 10 April 2003 (10.04.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0208785.6

17 April 2002 (17.04.2002) G

(71) Applicant (for all designated States except US): MEDI-CAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1B 4AL (GB).

(72) Inventors; and

WO 03/089001 A1

(75) Inventors/Applicants (for US only): MILNE, Stuart,


Angus [GB/GB]; The Fujisawa Institute of Neuroscience in Edimburg, h-Department of Neuroscience, The University of Edinburgh, Appelton Tower, Crichton Street, Edinburgh EH8 9LE (GB). JABBOUR, Henry, Nicolas [AU/GB]; MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, The University of Edinburgh Academic Centre, 49 Little France Crescent, Old Dalkeith Road, Edinburgh EH16 4SB (GB).

(74) Agent: MILES, John, S.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: FP RECEPTOR ANTAGONISTS OR PGF2 ALPHA ANTAGONISTA FOR TREATING PATHOLOGICAL CONDITIONS OF THE UTERUS



EP MP/LP ES LS

b

200
180
180
180
140
140
100
60
40
20
0
Cycle Cancer

(57) Abstract: A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents $PGF_{2\alpha}$, having its effect on the FP receptor. Typically, the pathological condition is uterine cancer, fibroids or endometriosis.

WO 03/089001 A1



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



Inte nal Application No PCT/GB 03/01521

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K45/00 A61K45/06 A61P15/00 A61P35/00

A61K38/04 A61K9/00

A61K38/16

A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) $IPC \ 7 \ A61K \ A61P$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BIOSIS, EMBASE, CHEM ABS Data, SEQUENCE SEARCH

WPI Da	ta, EPO-Internal, BIOSIS, EMBASE,	CHEM ADS DATA, SEQUENCE	SEARCH			
C. DOCUMENTS CONSIDERED TO BE RELEVANT						
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to daim No.			
x	ORLICKY D J ET AL: "A ROLE FOR PROSTAGLANDINS IN ESTROGEN GROW REGULATION" MEDICAL HYPOTHESES, vol. 25, no. 1, 1988, pages 1-6 XP008020403 ISSN: 0306-9877 part "Hypothesis" and "Conclustabstract	TH ,	1-31			
X Y	WO 00 17348 A (CHEMTOB SYLVAIN KRISHNA G (CA); HOPITAL SAINTE (CA)) 30 March 2000 (2000-03-30 claims page 4, line 33 -page 6, line 9	JUSTINE	1,6-9, 14,19,21 22-24			
X Furth	ner documents are listed in the continuation of box C.	Patent family members are listed	in annex.			
Special categories of cited documents: A' document defining the general state of the art which is not considered to be of particular relevance E' earlier document but published on or after the international filling date L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O' document referring to an oral disclosure, use, exhibition or other means P' document published prior to the international filling date but later than the priority date claimed		"T" tater document published after the international filing date or priority date and not in conflict with the application but died to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family				
Date of the a	actual completion of the international search	Date of mailing of the international sea	arch report			
8	August 2003	14/08/2003				
Name and n	nalling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Böhmerova, E				
PCT/ISA/2	(10 (second sheet) (July 1992)					



Inte nal Application No PCT/GB 03/01521

NOON DOCUMENTS CONSIDERED TO BE RELEVANT	701748 03/01321	
	Relevant to claim No.	
US 5 955 575 A (POTIER MICHEL ET AL) 21 September 1999 (1999-09-21)	1,6-9, 14,19,21 22-24	
claims column 2, line 23 - line 61 	22-24	
US 5 912 006 A (ERLITZ MARC D ET AL) 15 June 1999 (1999-06-15) claims 	22-24	
US 6 197 327 B1 (HARRISON DONALD C ET AL) 6 March 2001 (2001-03-06) claims	22-24	
GRIFFIN B W ET AL: "AL-8810: A NOVEL PROSTAGLANDIN F 2ALPHA ANALOG WITH SELECTIVE ANTAGONIST EFFECTS AT THE PROSTAGLANDIN F 2ALPHA (FP) RECEPTOR" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 290, no. 3, 1999, pages 1278-1284, XP000876534 ISSN: 0022-3565 the whole document	1-31	
KITANAKA J-I ET AL: "PHLORETIN AS AN ANTAGONIST OF PROSTAGLANDIN F 2ALPHA RECEPTOR IN CULTURED RAT ASTROCYTES" JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 60, no. 2, February 1993 (1993-02), pages 704-708, XP000876615 ISSN: 0022-3042 the whole document	1-31	
MILNE STUART A ET AL: "Prostaglandin (PG) F2alpha receptor expression and signaling in human endometrium: Role of PGF2alpha in epithelial cell proliferation." JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 88, no. 4, 20 April 2003 (2003-04-20), pages 1825-1832, XP000901513 ISSN: 0021-972X the whole document	1-31	
	21 September 1999 (1999-09-21) claims column 2, line 23 - line 61 US 5 912 006 A (ERLITZ MARC D ET AL) 15 June 1999 (1999-06-15) claims US 6 197 327 B1 (HARRISON DONALD C ET AL) 6 March 2001 (2001-03-06) claims GRIFFIN B W ET AL: "AL-8810: A NOVEL PROSTAGLANDIN F 2ALPHA ANALOG WITH SELECTIVE ANTAGONIST EFFECTS AT THE PROSTAGLANDIN F 2ALPHA (FP) RECEPTOR" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 290, no. 3, 1999, pages 1278-1284, XP000876534 ISSN: 0022-3565 the whole document KITANAKA J-I ET AL: "PHLORETIN AS AN ANTAGONIST OF PROSTAGLANDIN F 2ALPHA RECEPTOR IN CULTURED RAT ASTROCYTES" JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 60, no. 2, February 1993 (1993-02), pages 704-708, XP000876615 ISSN: 0022-3042 the whole document MILNE STUART A ET AL: "Prostaglandin (PG) F2alpha receptor expression and signaling in human endometrium: Role of PGF2alpha in epithelial cell proliferation." JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 88, no. 4, 20 April 2003 (2003-04-20), pages 1825-1832, XP000901513 ISSN: 0021-972X	





PCT/GB 03/01521

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. 🗓	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-5,12-24,27-31 relate to a compound defined by reference to a desirable characteristic or property, namely to compositions and uses of an agent that prevents PGF2 alpha having its effect on the FP receptor. This definition is considered to be unclear under Article 6 PCT as it is not clear which is/are the effect/s of PGF2 alpha on the receptor which should be prevented.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/compounds/methods/apparatus. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound/method/apparatus by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds defined in claims 6-11.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



information on patent family members

Inte onal Application No PCT/GB 03/01521

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0017348	Α	30-03-2000	AU	5722499 A	10-04-2000
			CA	2342960 A1	30-03-2000
			WO	0017348 A1	30-03-2000
			ĘΡ	1114151 A1	11-07-2001
			JP	2002526509 T	20-08-2002
US 5955575	A	21-09-1999	AU	1553199 A	12-07-1999
•••••			CA	2315644 A1	01-07-1999
			WO	9932640 A1	01-07-1999
			EP	1054983 A1	29-11-2000
			US	6300312 B1	09-10-2001
US 5912006	Α	15-06-1999	WO	0074632 A2	14-12-2000
			AU	4547599 A	28-12-2000
US 6197327	B1	06-03-2001	AU	735407 B2	05-07-2001
			ΑU	7697698 A	30-12-1998
			BŘ	9810089 A	08-08-2000
			ΕP	0988009 A1	29-03-2000
			JP	2002515069 T	21-05-2002
			NZ	502120 A	26-04-2002
			NZ	508130 A	01-03-2002
			WO	9856323 A1	17-12-1998
			US	6086909 A	11-07-2000
			US	6416779 B1	09-07-2002
			US	6572874 B1	03-06-2003
			CN	1263454 T	16-08-2000